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specific. Except for preschoolers, therapeutic management of patients with ADHD 
relied heavily on drug treatment.
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Trends In HosPITal admIssIons among men and Women above THe age 
of 60 lIvIng In sTockHolm and UPPsala coUnTIes In sWeden
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Objectives: To measure the change in the risk of first, second, and third hospitali-
zation and the change in the proportion of hospitalization-free men and women 
above the age of 60 living in Stockholm and Uppsala counties in Sweden between 
1972 and 2010. MethOds: Individuals were followed in national registers for hos-
pitalizations and deaths from all causes between 1972 and 2010. Censoring occured 
at whichever of the following events appeared first; hospitalization (first, second, 
thrid), death, or December 31, 2010. Survival analysis was used to determine the 
proportion of hospitalization-free individuals. Discrete time logistic regression 
was used to obtain the the relative risk (RR) of first, second and third hospitaliza-
tion. Results: An increase in the proportion of hospitalization-free individuals over 
time was observed for both men and women; for example 87% more 82 year-old 
men, born in 1928, were free of hospitalizations since the age of 60 compared to 
those born in 1912. Between the years 1972 and 2010, the average annual decrease 
in the risk of first hospitalization after the age of 60 was 1% for both men (RR: 
0.991, 95%CI: 0.991-0.992) and women. The average annual risk for hospitalization 
decreased for the second and thrid event as well; however the reduction was not 
significant. cOnclusiOns: With the increase in the proportion of elderly in the 
population, the number of individuals with chronic diseases may increase, leading 
to higher demand for medical and social care. We have observed downward trends of 
the risk of first, second, and third hospitalization after the age of 60, which could be 
explained by a postponement of severe morbidity to higher ages. Focus on primary 
care and changes in inpatient care in Sweden may also partly exaplain the annual 
reduction in the risk of hospitalization.
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Caron M.1, Emery M.P.1, Maier W.2
1Mapi Research Trust, Lyon, France, 2Mapi, London, UK
Objectives: Since the implementation of Pediatric Regulations/Legislations in the 
USA (Pediatric Research Equity Act - PREA) and in Europe (Pediatric Investigation 
Plans - PIPs), product development programs should include pediatric studies. The 
objective of this study is to review opinions (EMA) and requirements (FDA) given by 
both agencies in the case of sitagliptin (alone and combined) for the treatment of 
diabetes mellitus in children. MethOds: The EMA and FDA websites were explored 
to: 1) Identify the products marketed under the INN of sitagliptin (alone or in com-
bination), and 2) Identify the associated PIPs or PREA requirements. The search was 
performed on January 18, 2013. Results: Eight products were marketed in Europe 
[i.e., sitagliptin (Januvia, Ristaben, Tesavel, Xelvia) and sitagliptin + metformin 
(Janumet, Efficib, Ristfor, Velmetia)]. Four products were authorized in the USA [i.e., 
sitagliptin (Januvia); sitagliptin + metformin (Janumet, Janumet XR); sitagliptin + 
simvastatin (Juvisync)]. The FDA and the EMA provided the same opinion for sitag-
liptin alone, i.e., deferred pediatric study for patients aged 11 to 16. The FDA and the 
EMA disagreed on sitagliptin + metformin. The EMA granted a waiver for all subsets 
of the pediatric population on the grounds that the specific medicinal product does 
not represent a significant therapeutic benefit over existing treatments, while the 
FDA required a pediatric study under PREA for the treatment of type 2 diabetes in 
pediatric patients aged 11 to 16. As for sitagliptin + simvastatin, the FDA grants a 
waiver on the grounds that the product does not represent a meaningful therapeutic 
benefit over existing therapies for pediatric patients. cOnclusiOns: The FDA and 
the EMA have similar opinions except for the combination sitagliptin + metformin. 
One reason could be the higher prevalence of type 2 diabetes mellitus in children 
in the USA as compared to Europe.
InfecTIon – clinical outcomes studies
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Objectives: The objective of the present study was to assess the geographic cor-
relation between the incidence of Lyme disease (LD) and mortality due to certain 
degenerative neurologic diseases (DND) in the US. MethOds: For this ecological 
study, public data sources at the CDC were queried to quantify LD cases and DND 
deaths for the 5-year period 2002-2006. Alzheimer’s disease, Parkinson’s disease, 
and motor neuron disease were preselected as DND of interest. The separate 
datasets, for LD and DND, were combined by matching county and state names. 
Counties with at least 1 case of LD and at least 10 deaths due to DND were included 
in analyses. All analyses were performed in SAS. Results: Of the 3141 counties of 
the US, 1372 reported at least 1 case of LD, 2742 reported at least 10 deaths due to 
DND, and 1339 met both conditions and were therefore included in analyses. The 
observed number of LD cases and DND deaths for a single county ranged from 1- 
6407 (mean: 78; median: 3) and 10-9207 (mean: 165; median: 55), respectively. The 
Spearman rank test indicated that there is a fair degree of correlation between LD 
incidence and DND mortality (r= 0.44, p< 0.0001). In sensitivity analyses, (1) exclud-
ing outliers, defined as observations ≥ 99th percentile (LD> 53; DND> 1255), and (2) 
evaluating each disease separately, the correlation remained similar in magni-
tude and statistically significant (coefficient: 0.32-0.41; p< 0.0001). cOnclusiOns: 
There is a fair degree of correlation between LD incidence and DND mortality: 
US counties with a higher number of LD cases tend to have a higher number of 
Objectives: Anabolic-Androgenic Steroids (AAS) have been used for muscle mass 
development for over fifty years. The health outcomes of supraphysiologic doses of 
AAS have been debated, but most existing information pertains to men. This pur-
pose of the study is to use the National Longitudinal Study of Adolescent Health 
(AddHealth) to elucidate health outcomes of AAS usage in women. MethOds: 
A cohort study of female AAS users were assessed in two time periods six years 
apart. Baseline descriptive statistics were used to describe age, income, race, drug 
use, education, and work performed for the sample. Follow up health outcomes 
include diabetes, heart disease, hyperlipidemia, anger, physician visit, use of medi-
cal care in the last year, Body Mass Index (BMI), blood pressure (BP), C-reactive 
protein, and HbA1C. Each dependent variable was tested in independent logis-
tic regressions and in sensitivity tests using a MANOVA. Results: The sample 
included 49 female respondents. Education was associated with a two-fold greater 
odds of AAS use comparing those who attended vocational school to those who 
attended college (OR= 2.22, p= .03). Anger was associated with 88% greater risk of 
AAS use (OR= 1.88, p= .04). HbA1c in the pre-diabetic range, while not statistically 
significant may be associated with AAS use (OR= 1.85, p= .05). No other health 
outcomes were identified. cOnclusiOns: This study contributes to the literature 
of female AAS use showing little in health care usage and long term health conse-
quences. Anger is associated with male users but little research exists pertaining 
to this phenomenon in women. Elevated HbA1c is not commonly associated with 
AAS use, but due to the small sample size more research should assess AAS use 
among females.
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Objectives: As a basis for future safety evaluations of oral contraceptive (OC) use in 
Europe, current user and treatment characteristics were assessed in four European 
health care databases. MethOds: A descriptive retrospective database study was 
performed over 2009-2010 in GP databases from The Netherlands (IPCI), UK (THIN) 
and Italy (HSD) and linked pharmacy dispensing and hospital admission data from 
The Netherlands (PHARMO). Study follow-up started at the first OC prescription 
in 2009-2010 (users), one year after database entry or at Jan 1, 2009. Health indica-
tors at start of follow-up included BMI and previous diagnosis of, or use of drugs 
for selected chronic conditions. Also, previous diagnoses of deep vein thrombosis, 
pulmonary embolism, cerebrovascular disease, myocardial infarction, breast cancer 
and cervical cancer were assessed. Treatment characteristics of OC included his-
tory of use, type of OC (chemical substance) used during 2009-2010 and switches or 
discontinuations. Results: Among 4.9 million women, 14% had OC prescribed in 
2009-2010. In The Netherlands and UK, 12-16% and in Italy 6% had a record of OC 
use. The prevalence of OC recorded prescription at January 1, 2010 was 81 per 1000 
women of all ages and 271 per 1000 women aged 15-24, a much lower figure than 
what is recorded by surveys, probably due to switches between use and non-use 
and to reimbursement and/or prescription policies that reduce recording in GP data-
bases. Among the non-users in 2009-2010, up to 22% had a history of OC recorded 
use. Little differences in health indicators were found between users and non-users 
in the databases where the information was available. cOnclusiOns: Trends in 
health among European women in general also apply to OC users. However, OC use 
is not registered very well in health care databases which limits the possibilities 
of pharmacovigilance. Distribution channels and reimbursement policies vary, as 
well as recording in the databases.
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Objectives: To explore health care utilization and treatment patterns for atten-
tion-deficit/hyperactivity disorder (ADHD) in Germany, with particular emphasis 
on psychostimulant prescriptions. MethOds: The complete claims database of 
the organization of physicians registered with statutory health insurance (SHI) 
in Nordbaden/Germany was available for analysis, covering the total regional 
population enrolled in SHI (2.24 million lives). The dataset for years 2003 to 2009 
was reorganized as to allow patient-centered evaluation. For calendar year 2009, 
21,287 patients with ADHD (male, 15,108; female, 6,179; including 5,931 patients 
or 27.9% [male, 4,582; female, 1,349] with coexisting conduct disorder [F90.1 or a 
combination of F90 and F91 codes according to ICD-10]) were available for anal-
ysis. Results: Preschool children (age 0-5 years) with ADHD were prescribed 
medication in very rare cases (1.6% in 2009) and after an average lead time of 
more than one year only. Most received some form of nonpharmacological therapy 
or were left untreated (42%). In contrast, 41% of children (age group 6-12 years, 
since 2003, continuously increasing from 32%) and 54% of adolescents (age group 
13-17 years, rate remaining stable since 2006) were prescribed either stimulant 
(methylphenidate, MPH, or amphetamine) or nonstimulant (atomoxetine) drugs. 
Males and patients with concomitant conduct disorder were more likely to receive 
medication treatment. Modified-release MPH formulations were more widely used 
than immediate-release MPH. Overall use of medication increased steadily, from 
32.2% of ADHD patients in 2003 to 39.9% in 2009, whereas its rate decreased over 
time in adult patients (declining from 38% in 2003 to 26% in 2009). – Upon indi-
vidual review of all prescriptions of ADHD medication for members of the control 
group, no evidence was found supporting potentially inappropriate use of stimu-
lant medication. cOnclusiOns: Treatment patterns were highly age and gender 
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above treatments and with the following endpoints: Sustained Virological Response 
(SVR), discontinuation of all medications (overall/due to Adverse Events (AE)), 
and incidence of anemia, rash (all grades) and pruritus-common adverse events 
of cHCV treatment. A Bayesian NMA was performed for all endpoints, assuming 
fixed study effects. Unpublished SMV studies meeting the inclusion criteria were 
obtained. Results: Three studies met the inclusion criteria: 2 phase III RCTs (SMV 
n= 183; TVR n= 189), and 1 SMV phase IIb RCT (n= 92). Baseline characteristics were 
generally comparable for all studies. SMV shows a higher odds ratio (OR) of achiev-
ing SVR versus TVR (OR 1.68 (0.66-4.26)). SMV shows a lower OR of discontinuation: 
overall 0.35 (0.12-1.00) and due to AEs 0.87 (0.23-3.34) versus TVR. SMV shows a lower 
OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.42 (0.17-0.99) but a higher OR 
of experiencing pruritus 1.26 (0.46-3.47) versus TVR. The main limitation of this 
study is the small number of trials included in the analysis. cOnclusiOns: In this 
indirect comparison, SMV, in combination with PegIFN/RBV, showed a favourable 
risk-benefit profile compared to TVR with PegIFN/RBV in Japanese treatment-naïve 
Hepatitis C infected patients.
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Objectives: Two meta-analyses (York Health Economics Consortium [YHEC]; 
Cochrane) reported the beneficial effects of probiotics (live microorganisms which 
when administered in adequate amount confer a health benefit on the host). They 
demonstrated efficacy at reducing the duration and number of upper respiratory 
tract infections (URTI) and antibiotics use. The purchase of probiotics by consumers 
is likely to have positive externalities to the national health system and society. The 
aim of this analysis was to estimate the public health consequences of probiotics 
consumption, in France. MethOds: A 1/1,000 virtual age and gender standardized 
population was generated using a Markov model (TreeAge 2009). URTI risk factors 
were age, active/passive smoking, living in the community. Influenza like illness (ILI) 
and flu daily incidence rates came from Sentinelles, a practitioner network aimed 
at identifying flu outbreak. Epidemiologic data were used to differentiate cold, ILI 
and flu. One-day cycles were used over the 2011-2012 flu season. Probiotics effects 
came from two meta-analyses. Outcomes included numbers of URTIs days and 
episodes, antibiotics courses and sick leave days avoided with probiotics. Results: 
According to YHEC data, probiotics reduced URTI episodes (average 7 days) by -0.77 
days [-1.5;-0.04]. Extrapolating these results to the French population, probiotics 
would save 2.85 million URTI-days, the number of antibiotic courses would drop 
from 1,004,000 to 674,000 (difference about -330,000) and the number of sick leave 
days avoided in adults would be 653,000. According to Cochrane data, probiotics 
would reduce the probability to have an URTI episode by 0.58 [0.36;0.92] and anti-
biotic prescription by 0.67 [0.45;0.98]. The probiotic impact would become larger in 
terms of URTI-days avoided (-7.1 million), antibiotic courses (-509,000) and workdays 
lost (-1.2 million). cOnclusiOns: The probiotics public health impact on URTI is 
significant at a national level even though this analysis was restricted to the 1% of 
patients visiting a practitioner.
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Objectives: To predict the future incidence of chronic hepatitis C in Russia and assess 
potential impact of the available antiviral therapies (pegylated interferon a-2a/a-2b 
or standard interferon a-2b combined with ribavirin) on long-term morbidity and 
mortality rates in the population of newly diagnosed Russian patients with chronic 
hepatitis C. MethOds: Based on the national epidemiologic data and published natu-
ral history studies, the prognostic Markov model was developed. Depending on the 
results of antiviral therapy, patients’ flows over 25-year time frame were simulated. 
End points of interests included: the incidence of compensated and decompensated 
cirrhosis, hepatocellular carcinoma and cumulative time that patients will spend in 
each state, the number of patients, who will require liver transplantation, and HCV-
related mortality rates. Results: During years 2013-2017 about 276,000 new cases 
of chronic hepatitis C will be diagnosed in Russia. After 25 years since being diag-
nosed 130, 189 and 227 of 1,000 patients received pegylated interferon a-2a, pegylated 
interferon a-2b and standard interferon a-2b, respectively, will develop compensated 
cirrhosis. The cumulative time that patients will spend in compensated cirrhosis state 
will be 848, 1,218 and 1,482 patient-years, respectively. During the established time 
frame, there will be expected 25, 36 and 43 cases of hepatocellular carcinoma and 35, 
51 and 62 HCV-related deaths. 28, 40 and 49 patients, respectively, will require liver 
transplantation. cOnclusiOns: The findings from the present study provide the 
opportunity to plan volumes of medical care that will be required to Russian patients 
with chronic hepatitis C during 25 years since disease was first diagnosed. The treat-
ment with pegylated interferon alfa-2a is considered the most preferable strategy 
due to considerably lower long-term morbidity and mortality rates as compared to 
pegylated interferon a-2b and standard interferon a-2b treatment.
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deaths due to DND. This study is limited by its ecological nature and more rigor-
ous epidemiologic research is needed to elucidate the association between LD 
and DND.
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Objectives: High pill burden has been associated with poor adherence to HAART 
and adverse clinical outcomes. This study evaluated the impact of HAART as a 
single-tablet regimen (STR) and multiple-tablet regimen (MTR) on outcomes in 
HIV patients within the Veteran’s Affairs (VA) system. MethOds: A retrospective, 
cohort study assessed patient VA dispensation data for HIV medications during 
the study enrollment period (7/1/2006 to 9/30/2011). Patients were assigned to the 
following cohorts: STR if they received a HAART regimen of a single tablet/day or 
MTR if they received a regimen of ≥ 2 tablets/day and no single tablet/day regimen 
during the enrollment period. Patients were followed from the index date (start 
of HAART regimen) until the earliest of treatment discontinuation, end of study 
period, or last date of health care-related activity (eg, VA benefits file or death). 
Hospitalization and adherence (medication possession ratio [MPR] ≥ 95%) were 
evaluated. Multivariate cohort differences in outcomes were controlled for using 
Cox-proportional hazard and logistic models; covariates were measured during 
a 6-month baseline period. Results: In all, 15,602 patients (STR, n= 6,191; MTR, 
n= 9,411) met study criteria; average age of the study sample was 52 years. Both 
cohorts had similar CD4 counts (mean [SD]: 432.2 [282.8] vs 419.3 [280.9]; P= 0.287) 
but significantly fewer patients receiving STR vs MTR had an undetectable viral load 
at baseline (42% vs 46%, P< 0.001). During follow-up, significantly more STR patients 
were adherent compared to MTR patients (75% vs 55.7%, P< 0.001). STR patients were 
also significantly less likely to experience hospitalization compared to MTR patients 
(26.8% vs 31.3%, P< 0.001). After controlling for baseline covariates, STR patients 
had twice the odds of being adherent (OR: 1.98, P< 0.001) and 31% lower hazard of 
experiencing hospitalization during follow-up (HR: 0.69, P< 0.001). cOnclusiOns: 
Treatment with STR compared to MTR improves adherence rates and decreases 
hospitalizations in patients with HIV/AIDS.
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Objectives: Sofosbuvir (SOF) is a nucleotide polymerase inhibitor with excellent 
clinical efficacy in combination with ribavirin (RBV) for 12 weeks for patients who 
are chronically infected with hepatitis C virus (HCV) genotype 2. A decision-analytic 
Markov model evaluated the health outcomes of SOF+RBV compared with current 
treatment options for patients who are previously untreated, had no response to 
prior interferon treatment, or are unable to take interferon. MethOds: The analysis 
modeled 3 cohorts of chronic HCV genotype 2 patients with an average age of 50 
and 25% with cirrhosis at the start of treatment followed-up to 100 years of age from 
a US third-party payer perspective. SOF+RBV for 12 weeks was compared with 1) 
pegylated interferon (PegIFN)+RBV for 24 weeks in the treatment-naïve patients; 
2) PegIFN+RBV for 48 weeks in the treatment-experienced; and 3) no treatment in 
those unable to take interferon. Sustained virologic response (SVR) and adverse 
event rates were based on phase III clinical trials. Transition probability, utility, 
and cost estimates (in 2013 US dollars) were based on a literature review, public 
sources, and consensus by a panel of 4 hepatologists. Results: In the treatment-
naïve cohort, the SOF+RBV regimen resulted in an 83% decrease in the cases of 
liver disease complications including hepatocellular carcinoma, decompensated 
cirrhosis, liver transplant, and HCV-related death compared with PegIFN+RBV. The 
reduction of the listed liver disease sequelae was 59% in the treatment-experienced 
vs. PegIFN+RBV and 93% in the interferon-unable cohort vs. no treatment. The num-
ber needed to treat (NNT) with SOF+RBV rather than PegIFN+RBV to achieve one 
additional SVR was 6 in the treatment-naïve and 4 in the treatment-experienced 
cohorts. cOnclusiOns: SOF+RBV was projected to yield better health outcomes 
in genotype 2 patients compared to PegIFN+RBV, largely driven by superior efficacy, 
and the potential to cure those who are unable to take interferon-based therapies.
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Objectives: Simeprevir (SMV) is an oral, once-daily potent protease inhibitor for 
the treatment of chronic Hepatitis C genotype-1 infection (cHCV). In phase IIb/III 
RCTs conducted in Japan, SMV, in combination with peginterferon-α and ribavirin 
(PegIFN/RBV), demonstrated potent efficacy in cHCV genotype 1-infected patients 
relative to PegIFN/RBV and was generally safe and well-tolerated. Telaprevir (TVR) 
in combination with PegIFN/RBV is licensed for the treatment of cHCV in Japan. 
In the absence of head-to-head comparisons of TVR and SMV, we undertook a 
network meta-analysis (NMA) to examine the relative efficacy and safety of SMV 
and TVR in combination with PegIFN/RBV in a Japanese population. MethOds: A 
systematic review identified RCTs in Japanese treatment-naive patients with the 
